This report was first published by Endpoints News. To see the original version, click here
ATLANTA — The former president of Lilly Diabetes and his colleague have come back together to create 501 Ventures, a firm aiming to fund the science of next-generation metabolic health medicines.
“Some people believe that maybe the metabolic health story has been written. It’s still going to be written,” said Enrique Conterno, 501 executive chair, in an interview with Endpoints News at this year’s ObesityWeek conference in Atlanta.
您已閱讀17%（524字），剩余83%（2577字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。